← Leaderboards
Hong Tian
Everglades Biopharma, Llc
$1,523,811
Attributed
$2,896,366
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $981.9K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,896,366 · 5
By mechanism
R44$1,963,529 · 1
R43$707,837 · 3
R41$225,000 · 1
Top collaborators
- Wei Li5 shared
- Keith A Webster1 shared
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsSafetyAngiogenic FactorBindingNeutralizing Monoclonal AntibodiesMonoclonal AntibodiesVascular Endothelial Growth FactorsSignal PathwayTreatment EfficacyDiabetic RetinopathyResistanceAngiogenesisAngiogenesis InhibitorsPharmaceutical PreparationsRanibizumabSecretogranin IiiVascular DiseasesCombined Modality TherapySide EffectBlindnessAlternative TherapiesNeovascularBaseExtravasation
Grant awards (6)
Developing a novel therapy for diabetic retinopathy$981,661
R44 · FY2025 · EY · contact PI
Developing a novel therapy for diabetic retinopathy$981,868
R44 · FY2024 · EY · contact PI
A new drug entity for combination therapy of diabetic retinopathy$256,582
R43 · FY2021 · EY · contact PI
Next-generation ligandomics technology to globally map cellular ligands of the retina$226,255
R43 · FY2020 · EY · contact PI
Anti-angiogenic gene therapy of ocular vascular diseases$225,000
R43 · FY2020 · EY · contact PI
Developing a novel therapy for diabetic retinopathy$225,000
R41 · FY2017 · EY